Literature DB >> 8540716

Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas.

J Solera1, M Rodríguez-Zapata, P Geijo, J Largo, J Paulino, L Sáez, E Martínez-Alfaro, L Sánchez, M A Sepulveda, M D Ruiz-Ribó.   

Abstract

Brucellosis is a common zoonosis in many parts of the world; the best regimen for the treatment of brucellosis has not been clearly determined. We have carried out a multicenter, open, controlled trial in five general hospitals in Spain to compare the efficacy and safety of doxycycline and rifampin (DR) versus doxycycline and streptomycin (DS) for the treatment of human brucellosis. The study included 194 ambulatory or hospitalized patients with acute brucellosis, without endocarditis or neurobrucellosis. The diagnostic criterion was isolation of Brucella species from blood or other tissues (n = 120) or a standard tube agglutination titer of 1/160 or more for anti-Brucella antibodies with compatible clinical findings (n = 74). Patients were randomly assigned to receive either 100 mg of doxycycline twice daily plus rifampin, 900 mg/day, in a single morning dose for 45 days (DR group) or the same dose of doxycycline for 45 days plus streptomycin, 1 g/day, intramuscularly for 14 days (DS group). A lack of therapeutic efficacy developed in 8 of the 100 patients in the DR group (8%) and in 2 of the 94 patients in the DS group (2%)(P = 0.10). Relapses occurred in 16 of the 100 patients in the DR group (16%) but in only 5 of the 94 patients in the DS group (5.3%) (P = 0.02). When relapse was considered in combination with initial lack of efficacy, 26 patients in the DR group (24%) and 7 patients in the DS group (7.45%) failed to respond to therapy (P = 0.0016). In general, therapy was well tolerated and only four patients (4%) in the DR group and two (2%) in the DS group had episodes of adverse effects necessitating discontinuation of treatment (P> 0.2). We conclude that a doxycycline-and-rifampin regimen is less effective than the doxycycline-and-streptomycin regimen in patients with acute brucellosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8540716      PMCID: PMC162881          DOI: 10.1128/AAC.39.9.2061

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  Specific antibodies detected during relapse of human brucellosis.

Authors:  T Pellicer; J Ariza; A Foz; R Pallares; F Gudiol
Journal:  J Infect Dis       Date:  1988-05       Impact factor: 5.226

2.  A comparative study of therapeutic agents used for treatment of acute brucellosis.

Authors:  J M Feiz; H Sabbaghian; F Sohrabi
Journal:  Br J Clin Pract       Date:  1973-11

3.  The rose bengal plate agglutination test in the diagnosis of brucellosis.

Authors:  W J Morgan; D J MacKinnon; J R Lawson; G A Cullen
Journal:  Vet Rec       Date:  1969-12-06       Impact factor: 2.695

4.  [Brucellosis: a prospective study of 100 cases].

Authors:  J D Colmenero; J J Porras; P Valdivielso; J A Porras; E de Ramón; M Cause; C Juárez
Journal:  Med Clin (Barc)       Date:  1986-01-18       Impact factor: 1.725

5.  Determination of the in vitro sensitivity of Brucella strains to rifampicin.

Authors:  M J Corbel
Journal:  Br Vet J       Date:  1976 May-Jun

Review 6.  Brucellosis in the United States, 1960-1972. An abattoir-associated disease. Part I. Clinical features and therapy.

Authors:  T M Buchanan; L C Faber; R A Feldman
Journal:  Medicine (Baltimore)       Date:  1974-11       Impact factor: 1.889

7.  In vitro susceptibility of Brucella to various antibiotics.

Authors:  W H Hall; R E Manion
Journal:  Appl Microbiol       Date:  1970-10

8.  Brucellosis outbreak attributed to ingestion of umpasteurized goat cheese.

Authors:  E J Young; U Suvannoparrat
Journal:  Arch Intern Med       Date:  1975-02

9.  Antimicrobial susceptibility of clinical isolates of Brucella.

Authors:  J E Mortensen; D G Moore; J E Clarridge; E J Young
Journal:  Diagn Microbiol Infect Dis       Date:  1986-07       Impact factor: 2.803

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  37 in total

Review 1.  Use of aminoglycosides in treatment of infections due to intracellular bacteria.

Authors:  M Maurin; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

2.  Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.

Authors:  Ian M Rosenthal; Rokeya Tasneen; Charles A Peloquin; Ming Zhang; Deepak Almeida; Khisimuzi E Mdluli; Petros C Karakousis; Jacques H Grosset; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

3.  [A 37-year-old patient with fever, dyspnea and elevated transaminases after a stay in Mexico].

Authors:  Stephan A Schmid; Gabriele Birkenfeld
Journal:  Med Klin (Munich)       Date:  2010-04

Review 4.  Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies.

Authors:  Matthew E Falagas; Ioannis A Bliziotis
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 5.  New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Authors:  Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

6.  Brucella arteritis: clinical manifestations, treatment, and prognosis.

Authors:  Jesica A Herrick; Robert J Lederman; Brigit Sullivan; John H Powers; Tara N Palmore
Journal:  Lancet Infect Dis       Date:  2014-01-28       Impact factor: 25.071

7.  Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.

Authors:  R E Aarnoutse; G S Kibiki; K Reither; H H Semvua; F Haraka; C M Mtabho; S G Mpagama; J van den Boogaard; I M Sumari-de Boer; C Magis-Escurra; M Wattenberg; J G M Logger; L H M Te Brake; M Hoelscher; S H Gillespie; A Colbers; P P J Phillips; G Plemper van Balen; M J Boeree
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

8.  A sporadic outbreak of human brucellosis in Korea.

Authors:  Mi-Yeoun Park; Chang-Seop Lee; Young-Sil Choi; Seoung-Ju Park; Joo-Sun Lee; Heung-Bum Lee
Journal:  J Korean Med Sci       Date:  2005-12       Impact factor: 2.153

9.  Nondividing but metabolically active gamma-irradiated Brucella melitensis is protective against virulent B. melitensis challenge in mice.

Authors:  D M Magnani; J S Harms; M A Durward; G A Splitter
Journal:  Infect Immun       Date:  2009-08-24       Impact factor: 3.441

10.  Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs.

Authors:  Sylvain Goutelle; Laurent Bourguignon; Pascal H Maire; Michael Van Guilder; John E Conte; Roger W Jelliffe
Journal:  Antimicrob Agents Chemother       Date:  2009-04-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.